Cadrenal Therapeutics, Inc. CVKD 深 沪
等待开盘 07-29 09:30:00 美东时间
2.01
-0.050
-2.43%
华盛通- 最 高2.095
- 今 开2.06
- 成交量 3.27万股
- 最 低 1.98
- 昨 收 2.06
- 总市值 622.82万
- 52周最高 14.64
- 市盈率 静 --
- 换手率 1.06%
- 52周最低 1.86
- 委 比 79.30%
- 总股本 309.86万
- 历史最高 101.25
- 量 比 0.39
- 振 幅 5.58%
- 历史最低 1.86
- 每 手 1
- 风险率 3.70%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cadrenal Therapeutics Unveils Cardiac Critical Care Franchise, Seeks Partners For Late-Stage Cardiovascular Assets
Capital-efficient strategy focuses on differentiated therapies for cardiac pre- and post-operative critical care and orphan cardiovascular conditions Company is exploring development, licensing, and commercialization partnerships for CAD-1005, frunexian, and tecarfarin Recently presented Phase 2 CAD...
07-21 20:24
Cadrenal Therapeutics’ Late-Breaking Clinical Data From Phase 2 Study Of 12-LOX Inhibitor CAD-1005 Featured In Oral Presentation At ISTH 2026 Congress
Selected as one of three late-breakthrough abstracts: clinical trials and innovation in thrombosis, CAD-1005 took center stage before the global thrombosis community at the largest ISTH meeting in more than a decade. Oral presentation by Principal Investigator Dr. Steven E. McKenzie highlighted CAD-...
07-13 21:01
Cadrenal Therapeutics Says Late-Breaking Clinical Data On 12-Lipoxygenase Inhibitor, CAD-1005, Accepted For Oral Presentation At 34th Congress Of ISTH
Selection highlights the clinical value potential of Cadrenal’s first-in-class 12-lipoxygenase inhibitor for Heparin-Induced Thrombocytopenia (HIT) First-ever randomized, blinded, placebo-controlled trial in HIT, a life-threatening blood-clotting disorder triggered by an immune reaction to heparin, ...
06-24 20:04
Cadrenal Therapeutics Plans To Initiate Phase 2a Proof-Of-Concept Clinical Trial Of CAD-1005, Being Studied To Prevent Acute Kidney Injury In High-Risk Patients Undergoing Cardiac Surgery
New high-value indication for Phase 3-ready asset with data intended to support clinical development and strategic partnering discussions Additional billion-dollar target- Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI), a serious complication affecting 35,000 U.S. patients annually, with n...
06-15 20:34
Cadrenal Therapeutics Announces Participation In BIO 2026; To Host Partnering Meetings To Discuss Development And Commercialization Opportunities For Differentiated Pipeline, Headlined By CAD-1005 And Tecarfarin
Lead asset CAD-1005 being researched for prevention of life-threatening blood clots in patients with Heparin-induced Thrombocytopenia (HIT), targets $2 billion peak annual revenue potential12-LOX could play a central
06-03 21:05
Cadrenal Therapeutics Q1 EPS $(1.04) Beats $(1.62) Estimate
Cadrenal Therapeutics (NASDAQ:CVKD) reported quarterly losses of $(1.04) per share which beat the analyst consensus estimate of $(1.62) by 35.8 percent. This is a 50.24 percent increase over losses of $(2.09) per share
05-07 21:00
Cadrenal Therapeutics Receives FDA Guidance For Phase 3 Trial Of CAD-1005 Heparin-Induced Thrombocytopenia Treatment
Cadrenal has completed its End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) and receiving guidance on key elements of the Phase 3 pivotal trial for CAD-1005.The meeting with the FDA provided
04-30 20:37
美股大行评级 | 高盛首予PayPay“买入”评级；神经分泌生物科学获花旗等多家机构上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Enlivex"买入"评级，目标价从13美元升至20美元；韦德布什：维持FuboTV"跑赢大市"评级，目标价从3.5美元升至24美元
04-08 18:35
Cadrenal Therapeutics shares are trading higher. The company reported Q4 financial results.
Cadrenal Therapeutics shares are trading higher. The company reported Q4 financ...
04-01 03:35
Cadrenal Therapeutics Q4 EPS $(1.41) Misses $(1.18) Estimate
Cadrenal Therapeutics (NASDAQ:CVKD) reported quarterly losses of $(1.41) per share which missed the analyst consensus estimate of $(1.18) by 19.49 percent. This is a 49.64 percent increase over losses of $(2.80) per
03-31 22:15
